keyword
MENU ▼
Read by QxMD icon Read
search

Drug eluting beads

keyword
https://www.readbyqxmd.com/read/28710006/drug-eluting-embolic-microspheres-for-local-drug-delivery-state-of-the-art
#1
REVIEW
Katrin Fuchs, R Duran, Alban Denys, Pierre E Bize, Gerrit Borchard, Olivier Jordan
Embolic microspheres or beads used in transarterial chemoembolization are an established treatment method for hepatocellular carcinoma patients. The occlusion of the tumor-feeding vessels by intra-arterial injection of the beads results in tumor necrosis and shrinkage. In this short review, we describe the utility of using these beads as devices for local drug delivery. We review the latest advances in the development of non-biodegradable and biodegradable drug-eluting beads for transarterial chemoembolization...
July 11, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28706579/conventional-vs-drug-eluting-beads-transarterial-chemoembolization-for-hepatocellular-carcinoma
#2
REVIEW
Jeong Eun Song, Do Young Kim
Transarterial chemoembolization (TACE) is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC) according to the Barcelona Clinic Liver Cancer classification. The concept of conventional TACE (cTACE) is the selective obstruction of tumor-feeding artery by injection of chemotherapeutic agents, leading to ischemic necrosis of the target tumor via cytotoxic and ischemic effects. Drug-eluting beads (DEBs) have been imposed as novel drug-delivering agents for TACE, which allows for higher concentrations of drugs within the target tumor and lower systemic concentrations compared with cTACE...
June 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28705059/comparison-of-triple-drug-transcatheter-arterial-chemoembolization-tace-with-single-drug-tace-using-doxorubicin-eluting-beads-long-term-survival-in-313-patients
#3
Antoinette S Gomes, Phillip A Monteleone, James W Sayre, Richard S Finn, Saeed Sadeghi, Myron J Tong, Carolyn D Britten, Ronald W Busuttil
OBJECTIVE: We compared survival outcomes in 313 patients with unresectable hepatocellular carcinoma (HCC) treated with two different transcatheter arterial chemoembolization (TACE) regimens: triple-drug TACE or single-drug TACE using drug-eluting beads. MATERIALS AND METHODS: In this retrospective study, patient selection criteria were uniform. The triple-drug group (n = 166) underwent TACE using ethiodized oil with doxorubicin, cisplatin, and mitomycin-C with a microsphere embolic...
July 13, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28700244/targeted-yttrium-89-doxorubicin-drug-eluting-bead-a-safety-and-feasibility-pilot-study-in-a-rabbit-liver-cancer-model
#4
Johannes M Ludwig, Minzhi Xing, Yongkang Gai, Lingyi Sun, Dexing Zeng, Hyun S Kim
PURPOSE: To evaluate feasibility and safety of the cancer targeting (Radio)-Chemoembolization drug eluting bead (TRCE-DEB) concept drug SW43-DOX-L-NETA(89Y) DEB for the intra-arterial treatment of VX2 rabbit liver tumors. The treatment compound comprises of the Sigma-2 receptor ligand SW43 for cancer targeting, Doxorubicin (DOX), and 89Yttrium (89Y) as non-radioactive surrogate for therapeutic (Yttrium-90, Lutetium-177) and imaging (Yttrium-86) radioisotopes via the chelator L-NETA. MATERIAL AND METHODS: Ten New Zealand white rabbits with VX2 tumor allografts were used...
July 12, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28685382/safety-and-efficacy-of-transarterial-radioembolisation-in-patients-with-intermediate-or-advanced-stage-hepatocellular-carcinoma-refractory-to-chemoembolisation
#5
Elisabeth G Klompenhouwer, Raphaëla C Dresen, Chris Verslype, Annouschka Laenen, Gert De Hertogh, Christophe M Deroose, Lawrence Bonne, Vincent Vandevaveye, Geert Maleux
INTRODUCTION: Transarterial chemoembolisation (TACE) is the most widely used locoregional treatment for patients with an unresectable hepatocellular carcinoma (HCC). Transarterial radioembolisation (TARE) with yttrium-90 containing microspheres is an emerging interventional treatment that could be complementary or an alternative to TACE. AIM: To evaluate the safety and efficacy of TARE in patients with HCC who are refractory to TACE with drug-eluting beads (DEB-TACE)...
July 6, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28677067/intra-arterial-therapy-of-neuroendocrine-tumour-liver-metastases-comparing-conventional-tace-drug-eluting-beads-tace-and-yttrium-90-radioembolisation-as-treatment-options-using-a-propensity-score-analysis-model
#6
Duc Do Minh, Julius Chapiro, Boris Gorodetski, Qiang Huang, Cuihong Liu, Susanne Smolka, Lynn Jeanette Savic, David Wainstejn, MingDe Lin, Todd Schlachter, Bernhard Gebauer, Jean-François Geschwind
OBJECTIVES: To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolisation (cTACE), drug-eluting beads TACE (DEB-TACE) and yttrium-90 radioembolisation (Y90) for the treatment of liver metastases from gastroenteropancreatic (GEP) neuroendocrine tumours (NELM). METHODS: This retrospective analysis included 192 patients (58.6 years mean age, 56% men) with NELM treated with cTACE (N = 122), DEB-TACE (N = 26) or Y90 (N = 44) between 2000 and 2014...
July 4, 2017: European Radiology
https://www.readbyqxmd.com/read/28676199/the-art-score-is-not-an-effective-tool-for-optimizing-patient-selection-for-deb-tace-retreatment-a-multicentre-spanish-study
#7
Maria Pipa-Muñiz, Lluis Castells, Sonia Pascual, Javier Fernández-Castroagudín, Iratxe Díez-Miranda, Javier Irurzun, Roberto Díaz-Beveridge, María Senosiaín, Juan Arenas, Manuel de la Mata, Juan Turnes, María Isabel Monge-Romero, Daniel Pérez-Enguix, Javier Bustamante-Schneider, Nora Otegui, Esther Molina-Pérez, José Eduardo Rodríguez-Menéndez, Maria Varela
INTRODUCTION: The appropriate selection of hepatocellular carcinoma (HCC) patients who are eligible for transarterial chemoembolization (TACE) remains a challenge. The ART score has recently been proposed as a method of identifying patients who are eligible or not for a second TACE procedure. OBJECTIVE: To assess the validity of the Assessment for Retreatment with TACE (ART) score in a cohort of patients treated with drug-eluting bead TACE (DEB-TACE). SECONDARY OBJECTIVE: to identify clinical determinants associated with overall survival (OS)...
July 1, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28660787/comparison-of-pharmacokinetics-and-drug-release-in-tissues-after-transarterial-chemoembolization-with-doxorubicin-using-diverse-lipiodol-emulsions-and-callispheres-beads-in-rabbit-livers
#8
Shuisheng Zhang, Can Huang, Zhengzheng Li, Yongjie Yang, Tingting Bao, Haibo Chen, Yinghua Zou, Li Song
CalliSpheres(®) Beads (CB) is the first drug-eluting bead (DEB) product in China. Our aim was to compare the effect on the pharmacokinetics of doxorubicin (DOX) and its local concentration between lipiodol emulsions and CB in the process of TACE in rabbit livers. Twenty-five rabbits were distributed into two groups; Group 1 received lipiodol emulsions with DOX, and Group 2 received CB loaded with DOX (CBDOX). DOX was measured in the peripheral blood at different times after treatment. Livers were sampled at 1 week and 1 month for Group 2 after embolization...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28652049/evaluation-of-texture-analysis-parameter-for-response-prediction-in-patients-with-hepatocellular-carcinoma-undergoing-drug-eluting-bead-transarterial-chemoembolization-deb-tace-using-biphasic-contrast-enhanced-ct-image-data-correlation-with-liver-perfusion
#9
Christopher Kloth, Wolfgang M Thaiss, Rainer Kärgel, Rainer Grimmer, Jan Fritz, Sorin Dumitru Ioanoviciu, Dominik Ketelsen, Konstantin Nikolaou, Marius Horger
RATIONALE AND OBJECTIVES: This study aimed to evaluate the potential role of computed tomography texture analysis (CTTA) of arterial and portal-venous enhancement phase image data for prediction and accurate assessment of response of hepatocellular carcinoma undergoing drug-eluting bead transarterial chemoembolization (TACE) by comparison to liver perfusion CT (PCT). MATERIALS AND METHODS: Twenty-eight patients (27 male; mean age 67.2 ± 10.4) with 56 hepatocellular carcinoma-typical liver lesions were included...
June 23, 2017: Academic Radiology
https://www.readbyqxmd.com/read/28651746/the-management-of-colorectal-liver-metastases
#10
B Maher, E Ryan, M Little, P Boardman, B Stedman
Colorectal cancer remains a leading cause of cancer-related death in Europe. Approximately one-quarter of patients have synchronous hepatic metastases and metachronous liver metastases occur in a further 30%. The scope of surgery in management of colorectal metastases has evolved to include selected patients with extra-hepatic disease for whom R0 resection is considered feasible; however, locoregional treatments are increasingly recognised as viable management options in those patients deemed unsuitable for surgery and there is an expanding body of evidence regarding their ability to achieve local control and increase progression-free survival in the liver...
June 23, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28648803/sorafenib-in-combination-with-transarterial-chemoembolisation-in-patients-with-unresectable-hepatocellular-carcinoma-tace-2-a-randomised-placebo-controlled-double-blind-phase-3-trial
#11
Tim Meyer, Richard Fox, Yuk Ting Ma, Paul J Ross, Martin W James, Richard Sturgess, Clive Stubbs, Deborah D Stocken, Lucy Wall, Anthony Watkinson, Nigel Hacking, T R Jeffry Evans, Peter Collins, Richard A Hubner, David Cunningham, John Neil Primrose, Philip J Johnson, Daniel H Palmer
BACKGROUND: Transarterial chemoembolisation (TACE) is the standard of care for patients with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib improves survival in patients with advanced disease. We aimed to determine whether TACE with sorafenib improves progression-free survival versus TACE with placebo. METHODS: We did a multicentre, randomised, placebo-controlled, phase 3 trial (TACE 2) in 20 hospitals in the UK for patients with unresectable, liver-confined hepatocellular carcinoma...
June 22, 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#12
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28542038/hypoxia-as-a-target-for-drug-combination-therapy-of-liver-cancer
#13
Cressida Bowyer, Andrew L Lewis, Andrew W Lloyd, Gary J Phillips, Wendy M Macfarlane
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer deaths worldwide. The standard of care for intermediate HCC is transarterial chemoembolization, which combines tumour embolization with locoregional delivery of the chemotherapeutic doxorubicin. Embolization therapies induce hypoxia, leading to the escape and proliferation of hypoxia-adapted cancer cells. The transcription factor that orchestrates responses to hypoxia is hypoxia-inducible factor 1 (HIF-1). The aim of this work is to show that targeting HIF-1 with combined drug therapy presents an opportunity for improving outcomes for HCC treatment...
August 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28508253/image-guided-transarterial-chemoembolization-with-drug-eluting-beads-loaded-with-doxorubicin-debdox-for-unresectable-hepatic-metastases-from-melanoma-technique-and-outcomes
#14
Jack Rostas, Alda Tam, Takami Sato, Larry Kelly, Cliff Tatum, Charles Scoggins, Kelly McMasters, Robert C G Martin
PURPOSE: Hepatic metastasis from melanoma represents a therapeutic dilemma, with limited effective options for the 85% of cases deemed unresectable. Systemic agents confer toxicity and, along with traditional local hepatic arterial-directed therapies such as transarterial chemoembolization, have not led to a significant increase in survival. The aim of this study was to investigate the safety and dose-limiting toxicity of DEBDOX for the treatment of unresectable hepatic metastases from melanoma...
May 15, 2017: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/28480062/locoregional-and-systemic-therapy-for-hepatocellular-carcinoma
#15
REVIEW
Olumide B Gbolahan, Michael A Schacht, Eric W Beckley, Thomas P LaRoche, Bert H O'Neil, Maximilian Pyko
The management of hepatocellular carcinoma (HCC) remains challenging due to late presentation and the presence of accompanying liver dysfunction. As such, most patients are not eligible for curative resection and liver transplant. Management in this scenario depends on a number of factors including hepatic function, tumor burden, patency of hepatic vasculature and patients' functional status. Based on these, patients can be offered catheter based intra-arterial therapy for intermediate stage disease and in more advanced disease, sorafenib...
April 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28442142/predictors-of-therapeutic-effect-of-transarterial-chemoembolisation-using-drug-eluting-beads-for-hepatocellular-carcinoma
#16
Y Asayama, D Okamoto, Y Ushijima, A Nishie, K Ishigami, Y Takayama, N Fujita, H Honda
AIMS: To identify predictors of a therapeutic effect after transarterial chemoembolisation using drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between January 2015 and July 2015, tumour variables and angiographic data were collected for 25 patients (49 target lesions) after they had undergone the DEB-TACE procedure for HCC. The therapeutic effect was evaluated according to the Response Evaluation Criteria in Cancer of the Liver at follow-up dynamic computed tomography (CT) performed within 1-4 months after the procedure...
April 22, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28440086/debiri-plus-capecitabine-a-treatment-option-for-refractory-liver-dominant-metastases-from-colorectal-cancer
#17
Vincenzo Di Noia, Michele Basso, Valentina Marsico, Eleonora Cerchiaro, Sabrina Rossi, Ettore D'Argento, Antonia Strippoli, Giovanni Schinzari, Roberto Iezzi, Alessandra Cassano, Carlo Barone
AIM: This single institution Phase II study evaluated drug-eluting beads loaded with irinotecan (DEBIRI) plus capecitabine in pretreated patients with colorectal cancer liver metastases. PATIENTS & METHODS: Forty patients with liver-limited or liver-dominant disease, who have failed at least two previous lines of chemotherapy, underwent either four DEBIRI at 2-week interval or two DEBIRI every 4 weeks for bilobar or single-lobe metastases, respectively. Capecitabine was given at 1000 mg/m(2) twice daily on days 1-14 every 3 weeks...
April 25, 2017: Future Oncology
https://www.readbyqxmd.com/read/28436630/-clinical-investigation-on-transarterial-chemoembolization-with-indigenous-drug-eluting-beads-in-treatment-of-unresectable-hepatocellular-carcinoma
#18
Gang Chen, Ding Zhang, Yacao Ying, Zhifeng Wang, Wei Tao, Hao Zhu, Jingfeng Zhang, Zhiyi Peng
Objective: To evaluate the efficacy and safety of drug-eluding beads transarterial chemoembolization (DEB-TACE) in treatment of unrecectable hepatocellular carcinoma (HCC). Methods: The clinical data of 42 consecutive HCC patients undergoing TACE were retrospectively analyzed, including 20 cases received conventional TACE (cTACE group) and 22 cases received TACE with epirubicine-loaded microspheres (CalliSpheres (®)) (DEB-TACE group). MRI scans were performed 1 week before and 1, 3 and 6 months after initial therapy...
January 25, 2017: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/28384190/in-vitro-biologic-efficacy-of-sunitinib-drug-eluting-beads-on-human-colorectal-and-hepatocellular-carcinoma-a-pilot-study
#19
Steven Lahti, Johannes M Ludwig, Minzhi Xing, Lingyi Sun, Dexing Zeng, Hyun S Kim
PURPOSE: Sunitinib drug eluting beads (DEB) are a novel anti-angiogenic bead preparation for use in transarterial chemoembolization. However, systematic studies of sunitinib DEB's effect on cancer cells have not been reported. Herein, we assess their direct biologic efficacy against carcinoma cell lines and correlate cell viability with drug release in vitro. MATERIALS AND METHODS: Sunitinib-HCl (10mg/mL) in Milli-Q water was mixed with LC Bead® 300-500μm (Biocompatibles UK Ltd...
2017: PloS One
https://www.readbyqxmd.com/read/28373452/chemoembolization-with-drug-eluting-microspheres-loaded-with-doxorubicin-for-the-treatment-of-cholangiocarcinoma
#20
Camillo Aliberti, Riccardo Carandina, Donatella Sarti, Enrico Pizzirani, Gaetano Ramondo, Luca Mulazzani, Gian Maria Mattioli, Giammaria Fiorentini
AIM: To report clinical outcomes of transarterial chemoembolization (TACE) using drug-eluting beads (DEBs) loaded with doxorubicin for the treatment of unresectable intrahepatic cholangiocarcinoma (CCA). PATIENTS AND METHODS: We treated 127 patients with doxorubicin via TACE. Inclusion criteria were: diagnosis of unresectable CCA; indication for TACE, performance status (PS) 0-2, >3 months of life expectancy, >18 years old, written consent. TACE was performed using DEBs for 109 (86%) patients and polythylene glycol drug-elutable microspheres (PEG) loaded with doxorubicin for 18 (14%) patients...
April 2017: Anticancer Research
keyword
keyword
8544
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"